688105 Nanjing Vazyme Biotech
- 21.18
- +0.35+1.68%
Nanjing Vazyme Biotech News
Nuoweizan (688105.SH): A wholly-owned subsidiary has obtained two medical instrument registration certificates.
On August 7th, Gelunhui reported that Novozen (688105.SH) announced that its wholly-owned subsidiary, Nanjing Novozen Medical Technology Co., Ltd., recently received two Medical Instrument Registration Certificates issued by the National Medical Products Administration.
Nuoweizhan (688105.SH): Cumulative repurchase of 1.04% of its shares.
On August 2nd, Gelunhui reported that as of July 31, 2024, the company has repurchased 4,161,077 shares of the company's stock through the Shanghai Stock Exchange's centralized bidding trading system, accounting for 1.04% of the company's total share capital of 400,010,000 shares. The lowest price for the repurchase transactions was 18.80 yuan per share, the highest price was 28.65 yuan per share, and the total amount paid was 101,445,710.76 yuan RMB (excluding transaction fees).
Nanjing Vazyme Biotech's Unit Gets Approval to Sell Two Medical Devices in Europe
Novogene (688105.SH): Subsidiary's product obtains EU CE IVDR certification.
On July 16, Gelonhui reported that Nouveau Life Sciences (688105.SH) announced that some products of its wholly-owned subsidiary, Nanjing Nouveau Life Sciences Medical Technology Co., Ltd., have recently obtained EU CE IVDR certification and can be sold in EU countries and countries that recognize EU CE certification. The fully automatic medical PCR analysis system and matching sample preservation solution obtained by the company this time can be used with microfluidic chips (test kits) to control fluids through digital microfluidic chip technology, and complete nucleic acid extraction, amplification, and detection of the test sample in the microfluidic chip.
Private Companies Invested in Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) up 5.3% Last Week, Insiders Too Were Rewarded
Voluntary disclosure announcement of Noritz's 2024 interim performance forecast.
Nuoweizan (688105. SH) has spent 100 million yuan to repurchase 1.02% of its shares.
Zhicheng Finance and Economics APP learned that NOWIYIZAN (688105.SH) announced that as of June 28, 2024, the company had repurchased a total of 4.0866 million shares of the company through the Shanghai Stock Exchange system by centralized bidding trading method, accounting for 1.02% of the total share capital of the company. The minimum price of repurchase transaction was 22.63 yuan/share and the maximum price was 28.65 yuan/share. The accumulative payment was 100 million RMB (excluding transaction fees).
Annual equity distribution of Nuoweizan (688105.SH) in 2023: 1 yuan per 10 shares. Registration for stock rights on July 5th.
Nuoweizan (688105.SH) released the Annual Equity Dividend Implementation Announcement for 2023, implementing equity dividend rights...
Nuoweizan (688105.SH): Cumulative spending of 100 million yuan to repurchase 1.02% of shares.
On June 4th, Gelunhu announced that as of May 31, 2024, the company has repurchased a total of 4,086,577 shares of the company's stock through the Shanghai Stock Exchange system via centralized bidding trading, accounting for 1.02% of the total share capital of 400,010,000 shares. The lowest price for repurchase transactions was 22.63 yuan/share, the highest was 28.65 yuan/share, and the total amount paid was 100,009,947.66 yuan RMB (excluding transaction fees).
Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt Sensibly?
Novizan (688105.SH): A cumulative repurchase of 1.01% of the company's shares at a cost of 98.4017 million yuan
Glonghui, May 13, 丨 Novizan (688105.SH) announced that as of May 10, 2024, the company had repurchased a total of 4,0282 million shares through the Shanghai Stock Exchange system, accounting for 1.01% of the company's total share capital of 400,010,000 shares. The lowest price for the repurchase transaction was 22.63 yuan/share, the highest price was 28.65 yuan/share, and the cumulative payment amount was 98.4017 million yuan (excluding transaction fees).
A subsidiary of Novizan (688105.SH) and a subsidiary of Shanghai Pharmaceutical reached a cooperation on businesses such as Alzheimer's disease blood test products
Novi Zan (688105.SH) announced that Nanjing Novi Zan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company (“Novi...
Novizan (688105.SH) reported first-quarter results, net profit of RMB 5.216,400
Novizan (688105.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Novizan (688105.SH): Net profit of 4.5 million yuan to 5.5 million yuan for the first quarter is expected to turn a year-on-year loss into a profit
On April 17, GLONGHUI (688105.SH) announced that the first quarter of 2024 achieved operating revenue of 30,000 million yuan to 315 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will increase by -219 million yuan to 12.81 million yuan, an increase of -0.7% to 4% over the previous year. Net profit attributable to owners of the parent company was 4.5 million yuan to 5.5 million yuan in the first quarter of 2024. Compared with the same period last year (statutory disclosure data), it will increase 55.12 million yuan to 56.12 million yuan, an increase of 109% to 111% over the previous year, turning a loss into a profit. 20
Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14%
Novizan (688105.SH) subsidiary develops AD series diagnostic reagent products to obtain medical device registration certificate
Zhitong Finance App News, Novizan (688105.SH) announced that a series of diagnostic reagent products developed by Nanjing Novizan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained a “Medical Device Registration Certificate”, namely beta amyloid 1-40 (Aβ1-40) test kit (chemiluminescence method), beta amyloid 1-42 (Aβ1-42) test kit (chemiluminescence method), phosphorylated Tau217 protein (p-TAU217) test kit (chemiluminescence method, phosphorylated Tau181 protein (Tau181 protein) p- Tau181) test kit (chemical
Novizan (688105.SH) subsidiary and Yufang Medical reached a strategic cooperation in the field of AD blood testing
Zhitong Finance App News, Novi Zan (688105.SH) issued an announcement. In order to implement the Health China Action Plan, comprehensively strengthen and deepen strategic cooperation between the two sides in screening and testing business, and actively promote the health and welfare of the public, the company's wholly-owned subsidiary Nanjing Novi Zan Medical Technology Co., Ltd. (“Novi Zan Medical” or “Party A”) recently signed a “Strategic Cooperation Agreement” with Shanghai Yufang Medical Technology (Group) Co., Ltd. (“Yufang Medical” or “Party B” for short) on strategic cooperation between the two parties in the screening and testing business. Relying on their respective industry positions and resource advantages, the two sides follow the “prevention is greater than cure”
Novizan (688105.SH): A total cost of 56.9 million yuan to buy back 0.6% of the shares
Glonghui, April 1, 丨 Novizan (688105.SH) announced that as of March 29, 2024, Nanjing Novizan Biotechnology Co., Ltd. had repurchased 2,393,058 shares of the company's shares through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.60% of the company's total share capital of 400,010,000 shares. The highest price of the repurchase transaction was 25.00 yuan/share, the lowest price was 22.63 yuan/share, and the total amount of capital paid was RMB 56,902,963.07 (excluding transaction fees).
Private Companies Invested in Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) Copped the Brunt of Last Week's CN¥456m Market Cap Decline
Novizan (688105.SH): A total of 710,000 shares have been repurchased
Glonghui, March 1, 丨 Novi Zan (688105.SH) announced that as of February 29, 2024, the company had repurchased 710,000 shares of the company's shares through centralized bidding transactions, accounting for 0.18% of the company's total share capital of 400,010,000 shares. The highest price of the repurchase transaction was 25.00 yuan/share, the lowest price was 23.54 yuan/share, and the total amount of capital paid was RMB 17,238,348.68 (excluding transaction fees).
Analysis
Price Target
No Data
